Dr Philippe Guinot, MD, PhD, anaesthetist, is the author of numerous international scientific articles. He kept an hospital practice as an Internist until 2001.
From 1977 to 1994, he pursued his career in the pharmaceutical industry in business and drug development in executive positions for several international laboratories in Europe.
As VP Drug Development, he introduced several products on the market. He was also appointed Adjunct Professor of Medicine at the University of California, Davis, from 1992 to 1996. Dr Guinot then managed three US and French Biotechnology companies in France for 5 years.
Dr Guinot joined Crédit Agricole Private Equity (now Omnes Capital) in 2001 to create and lead the firm’s Life Sciences VC team as Senior Managing Partner of the Company). Under his supervision, he and his staff invested more than 120 M€ over ten years with an overall very satisfactory return, through 15 successful M&A and IPOs.
His major successes are Biovex, where he was the second largest investor when the company was sold to Amgen, PanGenetix (sold to Abbott), arGEN-X(IPO), and also Metabolic Explorer (Lead Investor and organiser of the very successful IPO on Euronext).
Since he retired in April 2011, he started his own consultant company, PhG Bioconsulting. He became then Chairman of the Board of iTeos Therapeutics (Belgium). He also advises in Funds Raising, and he initiated the set-up of a 50 M€ Fund dedicated to “Rare Diseases and Innovative Biotechnologies”, invested by AFM-Téléthon and FNA in 2013, and managed by Laurent Arthaud at Bpifrance Investissement. He chairs the Advisory Investment Committee of this Fund.
He acts predominantly as Senior Advisor to the Biotech Funds managed by Bpifrance Investissement.